Stay updated on Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.

Latest updates to the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, indicating a minor update to the page version and related metadata.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing the previous Revision: v3.6.2. This signals a new build of the page rendering, without altering the study details.SummaryDifference0.1%

- Check38 days agoChange DetectedThe page's revision tag was updated from Revision: v3.6.0 to Revision: v3.6.2, signaling a software version bump in the site metadata. This change does not modify study details, eligibility criteria, or any user-facing content.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page adds a recruitment update stating 'No longer looking for participants' and introduces new help/navigation sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study'. Additionally, the Intervention/Treatment header formatting was adjusted from 'Intervention / Treatment' to 'Intervention/Treatment'.SummaryDifference0.5%

- Check59 days agoChange DetectedThe page now displays revision: v3.5.5 at the bottom, replacing v3.5.4. This indicates a recent update to the site's revision label and rendering.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page revision label was updated to v3.5.4, replacing the previous v3.5.3, indicating a minor update to the page version.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.